Biotron (ASX:BIT) has angered shareholders on HotCopper as the results of its latest COVID-treating drug trial come up dusty. “There were no statistically significant differences between drug and placebo groups based on change in SARS-CoV-2 nasal viral load,” Biotron wrote. In other words – for clarity, at risk of being painful – the data of a trial using its drug BIT225-012 in COVID patients says it’s as effective as taking a vitamin. There was also the issue it produced COVID-like symptoms, which apparently confused things for researchers. This finance journalist, at least, can’t help but th…